ROCHESTER, Mich., Feb. 22, 2017 -- OptimizeRx Corp. (OTCQB:OPRX), the leading aggregator of pharmaceutical-sponsored services in electronic health record (EHR) platforms, will hold a conference call on Wednesday, March 8, 2017 at 4:30 p.m. Eastern time to discuss results for the fourth quarter and full year ended December 31, 2016. The financial results will be issued in a press release prior to the call.
OptimizeRx management will host the presentation, followed by a question and answer period.
Date: Wednesday, March 8, 2017
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-888-277-7060
International dial-in number: 1-913-312-0719
Conference ID: 7160482
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.
A replay of the call will be available after 7:30 p.m. Eastern time on the same day through March 29, 2017, as well as available for replay via the Investors section of the OptimizeRx website at www.optimizerxcorp.com.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 7160482
About OptimizeRx Corp
Based in Rochester, Michigan, OptimizeRx Corporation (OTCQB:OPRX) is a health technology software company that is revolutionizing the point of care experience through technology to improve clinical decisions and outcomes. OptimizeRx’s unique consumer and physician platforms help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.
OptimizeRx core product replaces drug samples with electronic trial vouchers and copay coupon savings that are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading electronic health record (EHR) platforms in the country, including Allscripts, DrFirst, NewCrop, Quest Diagnostics, Practice Fusion and other EHRs to reach over 500,000 healthcare providers. In turn, OptimizeRx promotes patient savings and support from the world’s largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, visit www.optimizerx.com.
OptimizeRx Contact:
Doug Baker, CFO
Email Contact
Tel (248) 651-6568 x807
OptimizeRx’s Investor Relations Contact:
Ron Both
CMA
Email Contact
Tel (949) 432-7557


Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 



